Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?

Author(s): Grazia D. Femminella, Dario Leosco, Nicola Ferrara, Giuseppe Rengo

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 15 , Issue 6 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The adrenergic system has an important role in normal central nervous system function as well as in brain disease. The locus coeruleus, the main source of norepinephrine in brain, is involved in the regulation of learning and memory, reinforcement of sleep-wake cycle and synaptic plasticity. In Alzheimer’s disease, locus coeruleus degeneration is observed early in the course of the disease, years before the onset of clinical cognitive signs, with neurofibrillary detected at the stage of mild cognitive impairment, preceding amyloid deposition. Thus, in the last years, a great interest has grown in evaluating the possibility of central adrenergic system modulation as a therapeutic tool in Alzheimer’s disease. However, evidences do not show univocal results, with some studies suggesting that adrenergic stimulation might be beneficial in Alzheimer’s Disease and some others favoring adrenergic blockade. In this review, we summarize data from both hypothesis and describe the pathophysiological role of the adrenergic system in neurodegeneration.

Keywords: Adrenergic receptors, Alzheimer’s disease, beta-blockers, functional recovery, locus coeruleus, neurodegeneration.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [665 - 671]
Pages: 7
DOI: 10.2174/1871527315666160518123201
Price: $65

Article Metrics

PDF: 34
PRC: 1